Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4

Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgraded the stock to "Underperform" citing management instability and weak visibility, while Goldman Sachs maintained its "Buy" rating, seeing long-term opportunities despite a challenging near-term outlook.